United States · FDA
FDA approval not reviewed here
Sleep apnea
See FDA labeling for the approved population and indication; this page covers the trial population only.
Loading research and source information…
Sleep apnea · Drug research
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Nov 5, 2026 · Sources last checked Nov 16, 2026
Inclusion Criteria: * Able to provide informed consent and stated willingness to comply with all study procedures and availability for the duration of the study * Overweight or obese (body mass index 25-40 kg/m2) * Clinically confirmed diagnosis of obstructive sleep apnea by one of the following methods: a. Polysomnography: AHI ≥15/hour sleep or b. Home sleep apnea testing: Respiratory event index (REI) ≥15/hour sleep * AHI: apnea-hypopnea index (apneas + hypopneas / total sleep time in hours) Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: * Known non-OSA related conditions associated with sleep disordered breathing (e.g., central disorder of hypersomnolence, neurological, neuromuscular, or pulmonary disorder) * Use of sleep-inducing medications (e.g. benzodiazepines, opiates, barbiturates) * Type 1 diabetes mellitus * History of diabetic ketoacidosis * Known hypersensitivity reaction to bexagliflozin or any of its constituents or any contraindication to bexagliflozin use * Severe, recurrent urinary tract or genital mycotic infections * eGFR\<30mL/min/1.73m2 at time of or within 4 weeks of enrollment in the study * Unable to complete/tolerate magnetic resonance imaging (MRI) due to severe claustrophobia or metallic implants. * Language barrier, mental incapacity, unwillingness or inability to understand. * Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant. * Currently or planning to take a SGLT2i prior to or during enrollment in the study * Currently or planning to follow a ketogenic diet pattern ("keto diet) prior to or during enrollment in the study * Currently or planning to follow an active weight loss program (including but not limited to use of supplements, medications, or surgery) prior to or during enrollment in the study * Currently or planning to follow an intermittent fasting diet plan prior to or during enrollment in the study * Currently or planning to take a GLP-1 receptor agonist prior to or during enrollment in the study . * Existing lower limb ulcer (due to diabetes or any cause) * Existing severe peripheral arterial disease with intermittent claudication and/or prior lower limb revascularization procedure * Concomitant administration of UGT inducers * Severe liver disease
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Sleep apnea
See FDA labeling for the approved population and indication; this page covers the trial population only.
Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
registry · NCT05612594 · Structured source fields
Source date: Aug 27, 2026 · Checked: Nov 16, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: RECRUITING. Phase: PHASE4. Conditions: Sleep Apnea.
Open original sourceFDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
Enrollment status comes from the registry; check the original record for current details.
Read trial record and posted resultsStudy ages: 18 Years and older. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): United States.
Sites marked recruiting: United States. Check the original registry record for locations and study-team contacts; overall recruiting status does not guarantee a local place.
Primary data collection: Sep 2027 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
No posted registry results are indicated in this source response. This does not establish that no results exist elsewhere.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1